Metagenomi (NASDAQ:MGX) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Metagenomi (NASDAQ:MGX) issued its quarterly earnings results on Monday. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.01), FiscalAI reports. Metagenomi had a negative net margin of 348.54% and a negative return on equity of 47.14%. The company had revenue of $1.25 million for the quarter, compared to the consensus estimate of $5.90 million.

Metagenomi Stock Down 4.3%

Shares of Metagenomi stock traded down $0.06 during trading hours on Monday, reaching $1.35. 226,238 shares of the stock traded hands, compared to its average volume of 231,084. The company has a 50 day moving average price of $1.45 and a 200 day moving average price of $1.69. The firm has a market capitalization of $50.82 million, a price-to-earnings ratio of -0.57 and a beta of 0.63. Metagenomi has a one year low of $1.25 and a one year high of $3.95.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Weiss Ratings upgraded Metagenomi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Wall Street Zen downgraded Metagenomi from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Institutional Investors Weigh In On Metagenomi

A number of large investors have recently made changes to their positions in the company. Renaissance Technologies LLC grew its stake in shares of Metagenomi by 276.3% during the 4th quarter. Renaissance Technologies LLC now owns 628,400 shares of the company’s stock valued at $1,018,000 after purchasing an additional 461,400 shares during the period. Jane Street Group LLC lifted its position in shares of Metagenomi by 341.6% during the 4th quarter. Jane Street Group LLC now owns 433,859 shares of the company’s stock valued at $703,000 after buying an additional 335,604 shares in the last quarter. Bridgeway Capital Management LLC lifted its position in shares of Metagenomi by 102.1% during the 4th quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock valued at $641,000 after buying an additional 200,000 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Metagenomi by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 305,908 shares of the company’s stock valued at $496,000 after buying an additional 14,018 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Metagenomi during the 2nd quarter valued at about $373,000.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.